Study Protocol:  
Open -label study of Maraviroc in Hospitalized Individuals Diagnosed with SARS -CoV-2 
[STUDY_ID_REMOVED]  
Version Date: 11/6/ 2020  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 1 of 30 
   PHILIP A . CHAN MD, MS  
Clinical Research Protocol  
OPEN -LABEL STUDY OF MARAVIROC IN HOSPITALIZED INDIVIDUALS 
DIAGNOSED WITH SARS -COV -2 
Version Date:  11/6/ /2020  
Commercial Product:  Maraviroc  
IND Number:  PIND  150411 , IND exempt  
Deve lopment Phase : Phase 1  
Sponsor:  Department of Medicine   
Principal Investigator:  Name:  Philip A. Chan MD,  MS   
Telephone:  (401) 793-2928   
Fax: (401) 793 -4709    
E-mail:  Philip_Chan@brown.edu   
Medical Monitor:  Name:  Timothy Flanigan MD  
Telephone:  (401) 639 2433  
E-mail:  tflanig an@lifespan.org  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 2 of 30 
 TITLE  Open -Label Study of  Maraviroc in  Hospitalized  Individuals 
Diagnosed with SARS -CoV -2 
  PRINCIPAL 
INVESTIGATOR  Philip A. Chan MD,  MS  
  SPONSOR   Department  of Internal  Medicine  
SITE  Rhode Island H ospital  
The Miri am H ospital  
  RATIONALE  CCR5 antagonism in SARS -CoV -2 may alter cell trafficking of 
inflammatory cells , reduce activation of platelets, and may have a role 
in reversing lymphopenia . Maraviroc may also have anti -viral 
properties related to bindi ng to SAR S-CoV -2 Main Prote ase beyond    
its mechanism as a CCR5 antagonist.  
  STUDY DESIGN  Single -arm, Open -Label, Proof -of-Concept  
  PRIMA RY 
OBJECTIVE  To establish wh ether Maraviroc, used at its approv ed dosage for HIV, 
is safe and effective in hospit alized  patients with SAR S-CoV-2. 
  SECONDARY 
OBJECTIVES  Investigate the relationship between reduction of inflammatory and 
other bio markers (such as IL -6, CCL5, etc.) later in the course of 
infection and avoidance of respiratory decompensation and death.  
  NUMB ER OF 
SUBJECTS  16 subjects  
  SUB JECT 
SELECTION  
CRITERIA  Inclusion Criteria : 
• Male or female ≥ 18 years of age at time of screening    
• Documentation of a SA RS-CoV -2 diagnosis as evidenced by 
positive S ARS -CoV-2 PC R within twelve  days at time of 
screening  
• Chest radiography co nsistent w ith multi -focal pneumonia or 
air-space disease  
• Written informed consent obtained from  subject  and ab ility for 
subject to comply w ith the requirements of the study.  
• Subject able to safely swal low pills  or receive Maravir oc 
throug h a nasogastric or  orogastric tube.  
Exclusion Criteria : 
• Subjects who are pregna nt, breast feeding, or unwilling to pra ctice 
birth control du ring participation in the study.  
• Subjects with the pr esence of a c ondition or abn ormality that in 
the opinio n of the Investigator s woul d compr omise the safety of 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 3 of 30 
 the pat ient or the quality of the d ata. This includes, but is not 
limited  to, recent myocardial  infarction in past 6 months, 
neurological, psychiatr ic, endocrin e, or neoplastic  diseases that 
are judged to interf ere with participa tion in  the study.  
• Subjects with k nown diagnosis of human immu nodeficien cy 
virus infection (HIV)  
• Subjects enrolled in anot her interventional trial (includi ng one for 
COVID -19) that exclud es participation  in other trials or  includ es 
a pote nt CYP3A inhibitor  or inducer (e.g. lopinavir -riton avir) .  
• Subjects with ESRD or severe renal failure who are taking potent 
(moderate or str ong) CYP3A inhibito rs or inducers  
 
  TEST PRODUCT, 
DOSE,  AND RO UTE 
OF 
ADMINIS TRATION  Maraviroc will be ad ministere d orally twice dai ly for seven days.     
    DURATION OF 
SUBJECT 
PARTICIPATI ON 
AND DUR ATION OF 
STUDY  Subjects will be on study for up to  35 days 
Treatment:  7 days  
Follow -up:  28 days 
The to tal duration of the study is  expected to be 4 months. 2 months 
for subject re cruitment, 1 for final subject follow -up and 1 mon th for 
data run-off and analysis . 
E  CONCOMMI TAN T 
MEDICATIONS  Prohibi ted: 
Lopinavir -Tenofovir  
Hydroxychloroquine  
Ivermectin  
  EFFICACY 
EVALUATIONS   
PRIMARY ENDPOINT  • In this pr oof-of-conce pt trial, the stud y team is  chiefly concerned 
with safety and tolerabilit y of Marav iroc in subjects diagnosed 
with SARS -CoV -2.  The primary endpoint  is rate of subjects  who 
complete the 7 -day co urse of Mara viroc without discontinuati on 
for serious adverse event  or death.  Additional  endpoints include 
the percent of study population reaching clinical im provement , 
defined as t ime fro m enrollment  to an improvement of two  points 
on a seven-category ordinal scale  (defined below) , at Day 7. 
SECONDARY 
END POINTS  • Time to improvement to Score of 2 or less (Days)   based on 
Ordinal scale : 1, not hospitalized with resumption of normal 
activities; 2, not hos pitalized,  but un able to resume normal 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 4 of 30 
 activities  OR hospitalized  pending dispositio n, not requiring 
COV ID-related c are; 3, hospitaliz ed, not requiring supplemental 
oxygen;  4, hospitalized, requiring supplemental oxygen;  5, 
hospitalized, requiring nasal hi gh-flow ox ygen t herapy, 
noninvasive mech anical ventilation, or both ; 6, hospitalized , 
requiring ECMO, in vasive mecha nical ventilation,  or both; and , 
7, death.  
• Change in biomarker  levels  (CCL 5, IL-6, Chi311 , etc) from time 
of enrollment  to completion of therapy  or live discharge  from  the 
hospi tal (whichever comes first)   
• 7-, 14- and 28-day all -cause -mortality   
• Days on mechani cal ventilati on 
SAFETY 
EVALUATIONS  Daily, multi -disciplinary safety monitoring  with interi m analysis after 
8 subjects have received four or more doses of Maraviroc . 
PLANNED INTERIM 
ANALYSES  Exposure -adjust ed rates of adverse events a nd those resulting i n 
discontinua tion will b e calculated at the point in which 8 patients have 
recei ved more than four doses of treatment. Serious adverse events 
will be monitored by the study team  on an ongoing basis throughout  
the study.  
  STATISTICS  
Analysis Plan  • Rates o f adverse eve nts by severity and rate of completion of 
therapy.   
• Change in biomarker s compared to clinical improv ement  
•  Percent of study population reaching clinical improvement at 
Day 7 will be compared to published results from Remde sivir 
for 5 or 10 Da ys in Patient s with Severe C OVID -19, and other 
available clinical trials including The Randomized  Evaluation 
of COVID -19 therapy ( RECOVERY) Trial . 
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 5 of 30 
 TABLE OF CONTEN TS 
 
1 BACKGROUN D ................................ ................................ ................................ .................  7 
2 STUDY RATIONALE  ................................ ................................ ................................ ........  9 
3 STUDY  OBJECTIVES  ................................ ................................ ................................ ....... 10 
3.1 Primary Objective  ................................ ................................ ................................ ....... 10 
3.2 Secondary Objectives  ................................ ................................ ................................ .. 10 
4 STUDY  DESIGN  ................................ ................................ ................................ .................  10 
4.1 Study Overview  ................................ ................................ ................................ ...........  10 
5 CRITERIA FOR EVALUATION  ................................ ................................ .....................  10 
5.1 Primary Efficac y Endpoi nt ................................ ................................ ..........................  10 
5.2 Secondary Efficacy En dpoints  ................................ ................................ ....................  10 
6 SUBJECT SELECTION  ................................ ................................ ................................ .... 11 
6.1 Study Population  ................................ ................................ ................................ .........  11 
6.2 Inclusion Criteria  ................................ ................................ ................................ .........  11 
6.3 Exclusion Cr iteria ................................ ................................ ................................ ....... 11 
7 CONCURRENT MEDICATIONS  ................................ ................................ ....................  11 
7.1 Allowed ................................ ................................ ................................ .......................  11 
7.2 Prohibited  ................................ ................................ ................................ ....................  12 
8 STUDY TREATMENTS  ................................ ................................ ................................ .... 12 
8.1 Method of  Assigning Su bjects to Treatment Groups  ................................ ..................  12 
8.2 Formulation of Test Product  ................................ ................................ .......................  12 
8.3 Supply of Study Medication at the Site  ................................ ................................ ....... 12 
8.4 Study Medication Accountability  ................................ ................................ ...............  13 
8.5 Measures of Treat ment C ompliance ................................ ................................ ...........  14 
9 STUDY PROCEDURES AND GUIDEL INES ................................ ................................ . 14 
9.1 Clinical  Assessments  ................................ ................................ ................................ ... 14 
9.2 Clini cal Laboratory Measurements  ................................ ................................ .............  15 
9.3 Research Laboratory M easurements  ................................ ................................ ...........  15 
10 EVAL UAT IONS BY VISIT  ................................ ................................ ...............................  16 
10.1 Screening/Enrollement  (Day  0) ................................ ................................ ...................  16 
10.2   Visit 1 (Day 1) ................................ ................................ ................................ ............  16 
10.3 Visit 2 (Day 2) ................................ ................................ ................................ .............  16 
10.4 Visit 3 (Day 3) ................................ ................................ ................................ .............  17 
10.5 Visit 4 (Day  4) ................................ ................................ ................................ .............  17 
10.6 Visit 5 (Day 5) ................................ ................................ ................................ .............  17 
10.7 Visit 6 (Day 6) ................................ ................................ ................................ .............  18 
10.8 Visit 7 (Day 7) ................................ ................................ ................................ .............  18 
10.9 Visit  8 (Day 8) ................................ ................................ ................................ .............  18 
10.10   Visit 9 (Day 9) ................................ ................................ ................................ ..........  18 
10.11    Post-Intervention Follow -up (Day 10 and  after till discharge)  ................................  19 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 6 of 30 
 10.12   Day of Discharge  ................................ ................................ ................................ ...... 19 
10.13   Post-Discharge Follow -up (perform every 3 days till Day 28)  ................................ . 19 
10.14   Final Visit  (Day 28) ................................ ................................ ................................ .. 19 
10.15   Early Withdrawal Visit  (In-hospital)  ................................ ................................ ........  19 
10.16   Early Withdrawal Visit  (Out-of--hospital)  ................................ ................................  20 
10.17   Death  ................................ ................................ ................................ .........................  20 
11 ADVERSE EXPERIENCE REP ORTING AND DOCUMENTA TION  ........................  20 
11.1 Adve rse E vents  ................................ ................................ ................................ ...........  20 
11.2 Serious A dverse E xperiences (SA E) ................................ ................................ ...........  21 
11.3 Medical Monitori ng ................................ ................................ ................................ .... 22 
12 DISCONTIN UATIO N AND REPLACEMENT OF SUBJECTS ................................ ... 22 
12.1 Early Discontinuation of Study Drug  ................................ ................................ ..........  22 
12.2 Withdra wal of Subjects  ................................ ................................ ...............................  22 
12.3 Replacement of Subjects  ................................ ................................ .............................  23 
13 PROTOCOL VIOLATI ONS  ................................ ................................ .............................  23 
14 DATA SAFETY MONITORI NG ................................ ................................ ......................  24 
14.1 Postura l Dizziness and Orthosta tic Hypotension  ................................ .................  24 
14.2 Cardiac Event s ................................ ................................ ................................ ..........  26 
14.3 Hepatotoxicity  ................................ ................................ ................................ ...........  26 
14.4 Other  Adver se Events  ................................ ................................ ................................ . 27 
14.5 Unan ticipated Adverse  Events  ................................ ................................ ....................  27 
15 STATISTI CAL METHODS AND  CONSIDER ATIONS  ................................ ...............  27• 
15.1 Data Sets  Analy zed ................................ ................................ ................................ ..... 28 
15.2 Demographic and Baseline Characte ristics  ................................ ................................ . 28 
15.3 Analys is of Primary Endpoint  ................................ ................................ .....................  28 
15.4 Analysis of Secondary Endpoints  ................................ ................................ ...............  28 
15.5 Interim Ana lysis ................................ ................................ ................................ ..........  28 
16 DATA CO LLECTION, RET ENTIO N AND MONITORING  ................................ ....... 28 
16.1 Data Collection Instrument s ................................ ................................ ........................  28 
  
16.2 Subject Confidentiality ................................ ................................ ................................  29 
17 ADMINISTRATIVE, ETHI CAL, REGULATORY CONSIDER ATIONS  ..................  29 
17.1 Protocol A mendments  ................................ ................................ ................................ . 30 
17.2 Institution al Revi ew Bo ards and Indepe ndent Ethics Committees  .............................  30 
17.3 Informed Consent Form  ................................ ................................ ..............................  30 
17.4 Publications  ................................ ................................ ................................ .................  31 
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 7 of 30 
 1 BACKGROU ND 
Severe Acute Respirator y Syndrome Coronavirus 2 (SARS -CoV -2) is the c ause of 
Coron avirus  disease  2019 (COVID -19) and was first reported in Wuhan, China in 
December 20191. Though a wide spectrum of clinical manifestations exists, p atients often 
present w ith mi ld upper respiratory  symptoms, progressing in some cases to a mult ifocal 
pneumo nia wi th multi organ compromise2. As the  natural history of SARS -CoV -2 is further 
understood, increased attention has been devoted to understanding d isease progression and 
notabl y severe respiratory  complications which are described as oc currin g after 7-14 days 
after the  onset  of illness. Initia l retrospective studies of confirmed COVID -19 cases in 
tertiary hospitals in  Hubei Province, China, revealed a range of 1 -20 days fo r the 
progression of respi ratory distress following illness onset1,2,3. The clinical course  of 
COVI D-19 infections appears t o have a high degree of heterogeneity, with some remaining 
relatively uncomplic ated, some progressing to a mo derate pneumonia, and o thers 
developing severe, p rogressive pneumonia characterized by dy spnea,  tachyp nea, a nd 
hypoxia. In creased levels of IL -6 and decreased levels of lymphocytes have been reported 
in severe illnesses in a retrospective cohort of patient s from Jinyintan and Wu han hosp itals. 
Older age a nd common comorbidities including hypert ension , diabetes, a nd cor onary ar tery 
disease have been as sociated with increased mortality3. 
In the negative randomized, controlled, open -label trial of Lopinavir -Ritonavir 
involving patien ts with  COVID -19 and oxyg en saturation of less than 94% on room air, 
70% of pa tients required suppl emental  oxygen and 15% required high -flow nasal cannula 
or non -invasive mechanical ventilation on  presentation. Only one patient required 
intubation on prese ntation, but 16%  would ev entually require mechanical ventilation during 
their hospita lization. At D ay 7, only 6% of the subjects  in the Lopinavir -Ritonavir  reached 
clinical impro vement of 2 points on a 7 -point ordinal scale . At day 14, 45.5% of subjects 
reached 2-point clini cal im provement, 15.2% of subjects had died , and 28% continu ed to 
require non -invasive and nasal cannula support.  This early  study highlight ed the length y 
duration  of hospitalization  and late progression of respiratory failure  in COVI D-19. 4 
SARS-CoV -2 is a n RNA coronavirus  that enters the cell through an en dosomal 
route , during which  the virus attaches  to Angiotensi n-Converting -Enzyme -2 receptor , 
subsequently endocytosed  into a vesi cle and released into the c ytoplasm o f the cell via 
cathepsin -cleav ed spike protein . The viru s can also attach to Transmembrane Serine 
Protea se 2 (TMPRSS2)  to directly enter the cell  via fusion  with the cell membrane. Once in 
the cell the viral mRNA is transcribed  via RNA -dependent RNA polymerase  to create  more  
 
1 Li Q, Guan X,  Wu P, et al. Early  Transmission Dynamics in Wuhan, C hina, of Novel Corona virus–Infected 
Pneumonia. N Engl J Med. 2020;382(13):1199 -1207. doi :10.105 6/NEJMoa2 001316 
2 Huang C, W ang Y, Li X,  et al. Clinical features of patients infected with 2019 novel coronavirus in W uhan, 
China. Lancet. 2020;3 95(10223):497-506. doi:10.101 6/S0140 -6736(20)30183 -5 
3 Zhou F, Yu T, Du R, et al. Clinical course and  risk factors for mortality of adult inpatients with COVID-19 
in W uhan, China: a retrospective cohort study. Lanc et. 2020;395(10229):1054-1062. doi :10.101 6/S0140-
6736(20)30566 -3 
4 Cao  B , Wang  Y, Wen  D,  et al.  A trial of lo pinavir -riton avir in adul ts hospitalized with severe COVID -19 
N Engl J Med. 2020. doi:10.1056/NEJ Moa2001282  
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 8 of 30 
 genome RNA. Additionally , sub-genom ic mRNA s are translated to create proteins 
including proteases  and replicates , such  as papain -like pro tease, 3C -like pro tease (also 
known as main protease) and  RNA -dependent  DNA polymerase (RdRp) . 5These proteins  
serve a s potential targets for anti -virals. Remdesiv ir, an anti -viral that rece ived FDA 
Emer gency Use Auth orization for use in COVID -19, targets RdR p. Other FDA approved 
medications  have b een identified as potential drugs to re-purposing.  Virtual screenin g of 
2388 FDA approved medications for binding affini ty to the SARS -CoV -2 3C-like protease 
(main protease ), which is essential  for processing t he polyproteins require d for viral 
assembly , revealed  the CCR5 -antognist Maraviroc  to have the second -highest binding 
affinity. Further  molecular  conformational  dynamic sim ulations and the MMPB SA 
approach a re ongoing to provide further estimation of the binding affinity of Maraviroc to 
binding site on the 3C-like protease.6  
A growi ng body of literature is addr essing the com plex pathop hysiology un derlying 
COVID -19 inf ections t o better understand  human respon ses to the nov el coronavirus . 
Given the similarit ies betwe en other coronaviruses, including  SARS -CoV -1, and S ARS -
CoV -2, pathogenes is of SARS -CoV -2 has been  extrapolated fr om SARS -CoV -1 disease in 
animal models . In senescent mouse models of SAR S-CoV -1 infec tion, increase d 
expression of chemokine mRNA was observed in the lungs early and late in the infection, 
in a “biphasic ” manner. Compared to cont rols, a >9-fold increase in  CCL5/RANTES and 4 -
fold increase in CCR2 mRNA  were detected around days 7-9 of infect ion, when 
histopathologic evidence of pneumonitis was noted. Additionally, inflammatory cells 
recruited to the lungs early and late in the infection corresponded to the bi phasic expression 
of aforementioned chemokines .7  
CCR5 antag onism may play a role in diminishing ac ute lung injury correlati ng to  
chemotaxis of neutrophils and ot her effector cells late in the course of Coronavirus 
infection.  Mouse models of acute lung in jury have  demonstra ted that treatment with a 
CCR5 antagonist , Maraviroc , significantl y reduc ed lung  neutrophil infiltration, inhibited 
lung edema formation, a nd prevented histological tissue alterations .8 In addition, in-vitro 
studies of Maraviroc  have dem onstrated  its ability to effectively inhi bit macrophage a nd 
dendr itic ce ll chemotaxi s.9    
  
 
5 Simmons G , Zmora P,  Gierer S, Heurich A, Pöhlmann S. Proteolytic activation  of the SARS -coronavirus 
spike protein: cutting enzymes at the cutting  edge of anti viral research. Antiviral Res. 2013;100(3):605 -614. 
doi:10.1016/j.antiviral.2013.09.028  
6 A. Shamsi, T. Moh ammad, S. Anwar, F. MohamedAl  Ajmi, A. Hussain, M.T. Rehman, A. Islam, M.I.  
Hassan  Glecaprevir and Maraviroc are high -affinity inhibitor s of SARS -CoV -2 main protease: possible 
implication in COVID -19 therapy . Bioscience Reports , 40 (2020)  10.1042/BSR202012 56 
7 Chen J, Lau YF, Lamirande EW, et al. Cellular Immune Respo nses to Severe Acute Respiratory Syndr ome 
Coronavirus (SARS-CoV) Infecti on in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of 
SARS-CoV Infection.  J Virol. 2010; 84(3):1289-1301. doi:10.112 8/jvi.01281 -09 
8 Grommes J, Drechsler M, Soehnlein O. CCR 5 and F PR1 me diate neutrophil recruitment in endo toxin-
induc ed lung injury. J Innate Immun. 201 4;6(1):111-116. doi:10.1159/000353 229 
9 Rossi R, Lichtner M, De Rosa A, et al. In vitro effect of anti-human immunodeficiency virus CCR 5 
antagonist maraviroc on ch emotactic activity of mono cytes, macrophages and den dritic cells. Clin Exp 
Immunol. 2011;1 66(2):184-190. d oi:10.1111 /j.1365-2249.2011 .04409. 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 9 of 30 
 Chitinase 3 -like 1 (Chi3l1, also called as YKL -40) is a powerful inhibitor of 
epithelial cell death and oxidant induced lung injury. Mice that lack Chi3l1 are par ticularly 
susceptible to the ravages induced by hyperoxia and other expo sures tha t induce Acute 
Lung Injury (ALI).10 Studies have demonstrated that the expression levels of Chi3l1 in the 
lung were significantly decreased by the RIG -like helicase (RLH) immun e activation, the 
well-defined host sensing mechanism of RNA viruses lik e SARS -CoV -2.11 These studie s 
may suggest that the expression levels of Chi3l1 can be used as a sensitive biomarker of 
SARS -CoV -2 infection that predict disease severity and progression .  
 Recognizing that the relatio nship between the imm une respo nse and ch emokine 
signa ling are dynam ic and complex, studies are needed to  explor e CCR5 antagonism as a 
possible the rapeutic target for  SARS -CoV -2 infections . This study  propose s that CCR5 
antag onism prior to the second wave of infl ammatory  mediator expre ssion may  reverse 
lympho id depletion a nd may alter cell trafficking of inflammatory cells, bo th increasing 
viral control capac ity and d ampening damage to lung tissue, respectively .  
2 STUDY RATIONA LE 
This pilot study seeks to establish that selective blockade  of the CC R5/CCL5 axi s as well 
as the potential anti -viral pro perties of Maraviroc  may redu ce disease severity.  This proof -
of-concept effo rt seeks to correlate differences in clinical outcomes t o differential cy tokine 
expression in the setting  of CCR5 antagon ism in patients infe cted with SARS -CoV -2. 
Maraviroc is FDA -approve d for the treatment of  CCR5 -tropi c HIV-1 and has a well -
documented  safety and tolerability record in previous trials in immun ocompromised HIV 
patients. Maravi roc was not show n to have signif icant e ffect on the QT segmen t, can be 
delivered via oral formulat ion, and can be delive red safely  to both patients with end -stage 
renal disease and dependence on hemodialysis12. For these rea sons, Maraviroc i s an ideal 
candidate to study as  a potential the rapy fo r hospitalize d patients wit h moderate -to-severe  
COVID -19. 
 
3 STUDY OBJECTIV ES 
3.1 Primary Objective  
The primary objective is to establish whether Maraviroc, u sed at its approved dos age for 
HIV, is safe, tolerable,  and effe ctive in  hospitalized  patients  with SARS -CoV -2. 
 
10 M. H. Sohn et al., The chitinase -like protei ns breast regression protein -39 and YKL -40 regulate hyperoxia -
induced  acute lung injury. Am J Respir Crit Care Med 182, 918 -928 (2010).  
11 B. Ma et al ., RIG -like Helicase Regulation of Chitinase 3 -like 1 Axis and Pulmonary Metastasis. Sci Rep 6, 
26299  (2016 ). 
12 Vourvahis M, Fang  J, Ch ecchio T, et al. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-
negative subjects with impaired renal function. HIV Clin Trials. 201 3;14(3):99-109. doi :10.131 0/hct1403-99 
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 10 of 30 
 3.2 Secon dary Objective s 
The secondary  objective is to investigate the  relationship between reduction o f 
inflammatory markers (such as IL -6, CCL5, etc.) and clinical outcomes , including 
avoidance of respiratory d ecompensation  and death . 
4 STUDY DESIGN  
4.1 Study Overvi ew 
This is a single-center,  single -arm, open -label tri al. Sixteen  hosp italized  patients  will be 
enrolled . Screening data will  be reviewed to determine subject eligibili ty. Su bjects w ho 
meet all inclus ion criteria and none of the exclu sion criteri a will be app roached for co nsent 
prior to entering  the study.  Each su bject  will receive 7 days of Maraviroc twice daily . Each 
subject will have blood samples checked at time of enrollm ent (Day 0), Day 3, Day 7, and 
Day 1 5 or time of live discharge (whic hever comes f irst) of the  study. The total duration of 
subject participation  will be five weeks . The total duration of the study is expected to be 1 6 
weeks.  
5 CRITERIA FOR EVALUATION  
5.1 Primar y Endpoint  
This proof -of-conce pt trial will evaluate  safety  and toler ability of Ma raviroc in SARS -
CoV-2 infected patients. The primary endpoint i s rate of pati ents who complete the 7-day 
course of Maraviroc  without discontinuation for ad verse event s, hospi talization,  or death.    
Additional  endpoints include t he percent of s tudy populati on reaching clinical 
improvement , defined as t ime fro m enrollment  to an improvement of two  points on a 
seven-category ordinal scale  (defined below) , at Day 7. 
5.2 Secondary Endpo ints 
• Time to clinic al improvement , defined as time fro m enrollm ent to an improveme nt of 
two points on a seven-category ordinal scale  (defined below)  or live discharge f rom 
the hospital , whichever  comes first  
o Ordinal scale : 1, not hospitalized with resumpti on of normal activities; 2, not 
hospitalized, but un able to r esume no rmal activiti es OR hospitalize d pending 
dispositio n, not requiring COVID -related care ; 3, hospitalized, not requiring 
suppleme ntal oxygen;  4, hospitalized, re quiring supplemental oxygen;  5, 
hospitalized, requiring nasal high -flow oxygen therapy, no ninvasiv e 
ventilation , or both ; 6, hospitalized , requiring ECMO, invasive mechanical 
ventilation, or both; and , 7, death.  
• Change in cytokine  levels  from ti me of enrollment  to completion of therap y or live 
discharge  from the hospital (whichever comes first)   
• 7-, 14- and 28-day all-cause -mortali ty  
• Time to improvement to Score of 2 or less ( days) 
• Days on mechanical ventilation  
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 11 of 30 
 6 SUBJECT SELECT ION  
6.1 Study Populati on 
Subjects with a diagnosis of SARS -CoV -2 who meet the inclusion criteria w ill be elig ible 
for p articipation  in this stud y.   
6.2 Inclusion Cr iteria  
• Male or female ≥ 18 years of age at time of screening    
• Documentation of a SA RS-CoV -2 diagnosis as evidenced by positive S ARS -CoV -2 
PCR within twelve  days at time of screening  
• Chest  radiography co nsistent w ith multi -focal pneumonia or air -space disease  
• Written informed consent obtained from  subject  and ab ility for subject to comply 
with the requirements of the study.  
• Subject able to safely swal low pills  or receive Maraviroc through  a nasogastric or  
orogastric tube.  
6.3 Exclusion Criteria  
• Subjects who are p regnant , breastfeeding, or unwilling to prac tice birth  control du ring 
partic ipation in the study.  
• Subjects with the p resence of a condition or abnormali ty that in the opinion of t he 
Investigator s would compromise the safety  of the subject  or the quality of the da ta. 
This includes, but is not limited to, recent  myocardial  infarction  in past 6 months, 
neurological, psychiatric, endocrine, or neoplastic disea ses that ar e judged to inte rfere 
with particip ation in the study.  
• Subjects with known diagnosis of human immun odeficiency virus infection (HIV)  
• Subjects enrol led in anot her interve ntional trial (including one for COVID -19) that 
excludes participation in ot her trials,  or includes a p otent CYP3A inhibit or of inducer  
(e.g. lopi navir -ritonavir)  
• Subjects with ESRD or severe renal failure who are taking po tent CYP3A  inhibitors  or 
inducer s 
7 CONCURRENT MEDICATIONS  
7.1 Allowed Medications and Treatments  
Diligent m edicatio n reconciliat ion will be performed between the primary inpatient team  
and study team. Reduction in dose or d iscontinuation of CYP3A inducers/inhi bitors, an ti-
hypertens ive medication s, and diuretics at ti me of  enrollment will be considered and 
individuali zed to each subject at the discretion of the inpatient team.  Remdesivir  and 
dexamethasone , if administered out side o f a clinical trial, are allowed.  
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 12 of 30 
 7.2 Prohibited  Medications and Treatments  
The following medications a re proh ibited during the study and adminis tration w ill be 
consid ered a protoc ol vio lation.   
• Lopinavir -Teno fovir  
• Hydroxychloroquine  
• Ivermectin  
8 STUDY TRE ATMENTS  
8.1 Method of Assigning  Subjects to Tre atment Groups  
Up to a  total of 16 individuals who have been diagnosed with S ARS -CoV -2 and agree to 
partic ipation in the stud y will be placed on Maraviroc 30 0 mg twice daily for 7 days.  
Given design as an early, p roof-of-concept trial, all patients  will be a ssigned to the 
treatment group. The re will b e no placebo co ntrol group; ho weve r, patients  who are 
withd rawn from  the trial  drug will be consented at time of enrol lment  about cont inuing 
biomarker surveillance  at standard scheduled monitor ing times (Day  0, 3, 7 and the earlie r 
occurring  timepoin t of disc harge or Day 15). Subjects  who stop Maraviroc prior to 
completion of Maraviroc  will not be replaced .  
By defini tion, Day 0 is day of enrollment  extending to adm inistration of first dose of 
Marav iroc. Day 1 of stu dy is day of first complete BID dos ing of Ma raviroc.   
8.2 Formulation  of Test Product  
Maravir oc will be suppl ied in the same formulat ion of S elzentry, developed  by ViiV 
Healthcare,  a glob al specialist in HIV  established in  2009 by Pfizer and GlaxoS mithKline.  
 
8.3 Suppl y of Study Drug at the Site  
Pfizer will  reimburse for s tudy drug obtained by  Lifespan Pharm acy.   
8.3.1 Dosage/Dosage Regimen  
• Maraviroc 300 mg  twice a day fo r patients n ot on concomitant  moderate or  
strong CYP3A inhibitors/inducers.  
• Maraviroc 150 mg twice daily  for patients unable to  tolerate 3 00 mg twice daily 
and for patients on moderate or strong CY3PA inhi bitors.  
• Maraviroc 600 mg t wice dail y for patients on moderate or strong CY3PA 
inducers.  
8.3.2 Dispens ing 
Maraviroc wi ll be dispense d by a Pharmacist  at the t rial site.  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 13 of 30 
 8.3.3 Administration I nstruction s  
Maraviroc can be administered t wice a day b y mouth with or withou t food. Marav iroc can 
also be crushed , mixed  with 60 mL sterile water,  and administered throug h a nasogastric or 
orogastric tube . Documen tation of admini stration wi ll be recorded  as per standard protocol  
of the inpatient unit . 
8.4 Measures of Treatme nt Compliance  
Medication Administration re cords from  site’s Electron ic Medical Record will be a udited 
daily to ensure tr eatment compliance.  
9 STUD Y PROCE DURES A ND GUIDELINES  
Prior to conduc ting any study -related activit ies, written informed consent and the Health 
Insura nce Portability and Accountab ility Ac t (HIPAA) au thoriz ation must be signed and 
dated by th e subject .  
9.1 Clinical Assessments  
9.1.1 Concomit ant Med ication s 
All concomitant medication and concurrent therapies will be documented during the 
Screening /Enrollment  Visit (Day 0), during  Study Days 1 -8, and at early  terminati on when 
applicable.  Do se, rou te, un it frequency of administration, and indic ation f or adminis tration 
and d ates of medication will be captured.  
9.1.2 Demographics   
Demographic information (date of birth, gen der, race)  will be recorded a t enrollment .  
9.1.3 Medical His tory  
The fol low will be recor ded at  Screening :  
• Date of onset and presence of sympt oms relate d to SARS -CoV -2 infection 
including  cough, sho rtness of breath,  fatigue, nausea, vomiting, dia rrhea, rash, 
abdominal pain, fever, chill s, loss of smell, etc.  
• Histor y of obesity, hemodi alysis , cardio vascular diseases (hyp ertension, known 
valvu lar disease, ca rdiomyopat hies an d/or L V systolic or diastolic dy sfunction), 
pulmonary disease (i ncluding OSA , COPD, asthma, inters titial lung disease, c ystic 
fibrosi s, bron chiect asis, lung transplan t, lun g cancer , pulmonary hypertensi on).  
9.1.4 Physical Examina tion 
A complete  physical examina tion w ill be performed by an Investigator  who is a physician 
at time of enrollment .  As to reduce healthcare worker exposure to S ARS-CoV -2, 
Invest igators may perform an abb reviated  physical exam at each  visit and utilize 
components of the physical e xam per formed by a qualified  staff member  (MD, N P, and 
PA) on the primary care team .   
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 14 of 30 
 9.1.5 Vital Signs 
Measurement of b ody temperature, blood pr essure,  pulse and  respirations will be 
performe d and recorded each day of study participation per routine clinical care .  
9.1.6 Oximetry  
Oximetry will be  measu red on room air and on cur rent oxygen -delivery  device wh ile the 
subject s are at rest during each visit  unless deemed unsafe to subject to do so ( e.g. patient 
requiring sub stantial amount of supplemental oxygen ).  
9.1.7 Other Clinical Procedures  
• Imaging obtained as par t of routine clinical care with be revie wed.  These will 
include  chest -imaging and CT imaging.   
• Thromboelast ography, if obtained part of routine  care will also be  review ed and 
documented . 
9.1.8 Advers e Events  
Adverse event information will be elicited  during each study  visit. In an e ffort to  reduce 
healthcare  worker exposure to SARS-CoV -2, Investigators  will speak with subjects over 
the phone p rior to e ntering the room to perform an abbreviated  physica l exam. I f a subject 
is unable to participate in a telep honic inter view, an Investigator  will perform an inter view 
to elicit adver se eve nts in the s ubject ’s room . Appropriate documentation in case repo rt 
forms will reflect subjects who are un able to participate in conversation  due to altered 
mental status o r mechanical ventilation . In addition , all clinica l documentation obtained by 
nursing staff , as per clinical policy and  standard s of care, will be reviewe d daily for 
informati on pertaining to  adver se events . Duration (start and s top dates and times), 
severity/g rade, outcome, treatment,  and relation to stu dy drug will be recorded on the case 
report form (CRF)  as detailed in  Section 1 4. 
9.2 Clinical Laboratory Me asurements   
9.2.1 Hematolo gy 
Blood will be obt ained per sta ndard  of care  and sen t to trial site ’s hematology lab  for a 
complete blood count (hemoglobin, hema tocrit, red blood cell count, white  blood cell 
count, white blood cel l differential  including absolute n eutrophil cou nt, abs olute bands, 
absolute  lymphocyte count)  and pl atelet co unt) , serum C -reactive protei n (CRP ) and 
thromboelastography .  
9.2.2 Blood Chemis try Profile  
Blood will be obtained per standard of care an d sent to trial site’s chemistry l ab for 
determ ination  of  serum so dium, potassium , chlori de, bicarb onate,  random glucose, BUN, 
creatinin e, aspa rtate aminotransfer ase (AST/SGOT ), alanine aminotransfe rase 
(ALT/SGPT), alkali ne phosphatase,  total bilirubin, direct bilirubin, albumin , LDH , brain 
natriuretic peptide (BNP), D-dimer, troponin and lactate.  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 15 of 30 
 9.3 Research L abora tory Measurements   
All samples collected during the  study will be labeled with a de -identified, randomly 
generated  specimen ID .  Blood samples collec ted will be shipped overnight to InCell Dx  at 
1541 Industrial Road San Carlos , CA , 94070 . InCellDx, a diagnostics company  perform 
PBMC purification  upon receiving samples , and will  bank specimen s to perform analysis 
on blood samples , including a  cytokine panel that will consist of   sCD40L, GM -CSF, IF N 
gamma, IL -2, IL -4, IL -6, IL -8, IL -10, RANTS, TNF -alpha, and VEGF . Using PB MCs, 
InCellDx will also perform a CCR 5 Receptor occupancy analysis.  If enough plasma and 
PBMC samples are banked, banked samples will be sent to the The Prli c Lab at the Fred 
Hutchinson Cancer Cen ter near the end of the study . The Prlic Lab will perform  additional  
flow cytometric anal ysis to provide insight regarding the immune  subset distribution and 
state of activation  of the immune system.  Additionally, up to three 100 ul alliqots of banked 
plasma will be sent to  The El ias Lab at Brown University , who will pe rform analysis on  
Chitinase  3-like 1 (Chi3l1 ) at the end of the study  period . Remainin g specimen will be 
stored at InCellDx  for up to six months after th e end of the study , during which 
arrangements will be made to return remaining specime n to Lifespan /The Miriam Hospital 
Infection Diseases And Immunology C enter . Remaining specimens will be destroyed 5 
years after return to Lifespan . Until that time, t hese remaining specimens  may be  used for 
validation of results or may be used for further  research  studies.      
10 EVALUATIO NS BY VISIT  
10.1 Screenin g and Enrol lment Vi sit (Day  0) 
• Review the study with the subject  and obtain w ritten informed consent  
• Assign the subject a  unique subject  number . 
• Record demographic s data.  
• Recor d relevant medica l history . 
• Record  concomitan t medications.  
• Perform  a complet e physical examination.  
• Perform a complete review o f systems including symptom s of postural  dizziness  
• Perfor m and record v ital signs.  
• Perform and record oximetr y on r oom air and o n curr ent oxygen -deliverin g device . 
• Perform a nd re cord results of b lood pressur e testing , including orthostatic vital 
signs . 
• Document and review blo odwo rk obtained from standard  clinical care (chemis try, 
hematology,  hepa tic function) . 
• Collect blood sample for research  laborator y test (s):  Biomarkers . Collect 
information on QTc i f an electro cardiogram  is performed per rout ine clinical care . 
• Document and rev iew chest imaging  findings if  perfor med per routine clinical car e. 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 16 of 30 
 10.2 Visit 1 (Day  1) 
• First dos e of Ma raviroc Administered  in morn ing. Study member will be prese nt for 
first administrat ion 
• Perform interview with patient. Docu ment any Adverse Even ts. 
• Document c omplete  physical exam . 
• Perform and document  medications review . 
• Perform and record vital signs . 
• Perform and record oxi metry on room air and  on current oxygen -delivering d evice.  
• Reco rd any events including  transfer to intensive care, intubation , hospice r eferra l. 
• Document laboratory  values  and imaging  obtai ned as part of  routine standard o f 
care. 
10.3 Visit 2 (Day  2) 
• Review and  document Medication Administration Record for Day  1 of study . 
• Perform interview with patient. Recor d any Adverse Events.   
• Document  complete  physical exam . 
• Perform and record vital signs . 
• Perform and rec ord oximetry on room air and on c urren t oxygen -delive ring device.  
• Record any events inclu ding transfer to intensive care, intubation, hospice  referral . 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.4 Visit 3 (Day  3) 
• Review and document Medicat ion Admin istration Record  for Day 2 of study . 
• Perform interview with  patient. Record any Adv erse Events.   
• Document c omplete  physical ex am. 
• Perform and record vital si gns. 
• Perform and record oximetry on room air and on current oxygen -delivering de vice.  
• Record any ev ents inc luding trans fer to intensive care, intubation, hosp ice referral . 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Collect blood sample for research  laborator y test (s):  Biomarkers . 
 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 17 of 30 
 10.5 Visit 4 (Day 4) 
• Review and document Medication Adm inistration Record  for Day  3 of study . 
• Perform interview with p atient. Record any Adve rse Events.  
• Document c omplete  physical e xam. 
• Perform and record vital signs . 
• Perfo rm and recor d oximetry on room air and on c urrent oxygen -delivering device.  
• Record any e vents including  transfer to intensive c are, intubation, hospice  referral . 
• Document laboratory  values  and imaging  obtai ned as part of rou tine standard o f 
care. 
10.6 Visit 5 (Day 5)  
• Review and document Medication Administration Record  for Day  4 of study . 
• Perform interview with p atient. Recor d any Adverse Events.   
• Docu ment c omplete  physical exam . 
• Perform and record vit al signs . 
• Perform and record oximetry on ro om air and on current oxygen -delivering  device.  
• Record any events including  transfer to intensi ve care, intubat ion, hospice refe rral. 
• Document laboratory  values  and imag ing obtai ned as part of routine standard o f 
care. 
10.7 Visit 6 (Day 6 ) 
• Review and document Medication Ad ministration Record  for Day  5 of study . 
• Perform interview with pat ient. Record any Adverse Events.   
• Docum ent c omplete  physical exam . 
• Perform and record vita l signs . 
• Perform and record oximetry on room air an d on current  oxygen -delivering device.  
• Reco rd any events including  transfer to intensive care, intubation, hospice referr al. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.8 Visit 7 (Day 7) 
• Review and document Medication Administrat ion Record  for Day  6 of study . 
• Perform interview with patient. Record any Adverse Events.   
• Document c omplete  physical exam . 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 18 of 30 
 • Perform and record vita l signs  
• Perform and record oximetry  on room ai r and  on current oxygen -delivering device.  
• Record any ev ents includi ng transfer to intensive care, intubation, hospice referra l. 
• Document laboratory  values  and imagi ng obtai ned as part of routine standard o f 
care. 
• Collect b lood sample f or research  laborato ry test (s):  Biomarkers  
10.9 Visit 8 (Day 8) 
• Review and document Medication Administratio n Record  for Day  7 of study . 
• Perform interview with patie nt. Record any Adverse Events.   
• Document c omplete  physical exam . 
• Perform and record vital signs  
• Perform and record oximetry on room air and  on current o xygen -delivering device.  
• Record a ny event s including  transfer to intensive care, intubati on, hospice ref erral. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
10.10  Post-Intervention Follo w-up (Day 9 and every third day  prior to  discharg e) 
• Perform  interview with patient . Record any Adve rse E vents.   
• Perform and record vital signs . 
• Perform and record oximetry on  room  air and on current  oxygen-delivering device.  
• Record any event s includin g hospitaliz ation, intubation, intens ive-care admission . 
• Document  laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Obtain blood  sample s for research  laboratory test  on Day 1 5 
10.11  Day of Di scharge  
• Perform interview with patient . Record any Adverse E vents.   
• Perform and r ecord vital signs . 
• Perform and record oximetry on r oom air a nd on current  oxygen -delivering device.  
• Document laboratory  values  and imaging  obtai ned as part of routine standard  of 
care. 
• Record discharge destination , oxygen req uirement at time of discharge . 
• Obtain research  labwork  if discharge occurs earlier than Day 1 5 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 19 of 30 
 • Schedule p ost-discharg e phone follow -up. 
10.12  Post-Dischar ge Follow -up (perform weekly  till Day 35) 
• Perform phone i ntervie w with patient. Rec ord any Adverse Events.  
• Revi ew and document h ome medications . 
• Review and document pat ient acquired vitals . 
• Record any eve nts including h ospitalization,  intubati on, inten sive-care adm ission . 
10.13   Final Vi sit (Day 35) 
• Inform subject thi s will be the final visit of the study . 
• Perform interview with patient. Record any Adverse Events.  
• If in hospital , record findings from abbreviated  physical  examination.  
•  If in hospital , perform and reco rd vital signs .  
• If in hospital , perform and re cord oximetry  on room air and on current oxygen -
deliv ering device.  
• If in hospital, document laboratory  values  and imaging  obtai ned as part of routine 
standard o f care . 
• If in hospital , record  any events including intubation, intensive -care adm ission, 
change to comfort m easures, hospice re ferral or transfer . 
10.14   Early Withdrawal  Visit (In-Hospital)  
• Review  and document Medication Administra tion Record . 
• Perform a nd record vital sig ns, including orthos tatic vital signs . 
• Perform and record oximetry on room a ir and on curre nt oxy gen-delivering devi ce. 
• Document laboratory  values  and imaging  obtai ned as part of routine standard o f 
care. 
• Assent to collect blood sample f or clinical laboratory t ests:  Biomarke rs at Day 3 
and Day 7. 
• Record any events including intubation , intensive -care admission , chang e to 
comfor t measures,  hospice re ferral or transfer . 
10.15   Early Withdrawal  Visit  (Out-of-Hospital ) 
• Review and document home m edications . 
• Review an d doc ument pat ient acquired vi tals. 
• Document  subjects ’ current location of care type (e.g.  acute rehabilit ation  center) . 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 20 of 30 
 • Record any events i ncluding intubation, intensiv e-care admission , change to 
comfort measures, change to do not hos pitalize ( DNH) , hospice re ferral or t ransfer. 
10.16   Death  
• If in hospit al, review  and document Medication Administration Record. Document 
laboratory  values  and imaging  obtai ned as part of routine standard o f care . 
• Revi ew and docum ent time and cause of death . 
• Inform IRB of subject  death . 
• Record any preceding events including hospitalization , intubation, intensive -care 
admission , change to co mfor t measure s, hos pice re ferral or transfer . 
 
11 ADVERSE EXPERIENCE REPORTING AND D OCUMENTATION  
11.1 Adverse Events  
An adverse event  (AE) is any untowa rd medical occurrenc e in a clin ical investigation of a 
patient administ ered a pharmaceutical produc t and does not ne cessarily have a causal 
relationship with the treatment.  An AE is there fore any unfa vorable and un intended sign 
(includi ng an abnormal labo ratory finding), sym ptom o r disease temporally associated with 
the administration of an invest igational product, whe ther or not  it is related to that 
investigational product.  An unexpected AE i s one of a ty pe not identif ied in nature, 
severity, or frequen cy in the current In vestigator’s  Brochure or of greater severity or 
frequency than expected based o n the inf ormat ion in the In vesti gator’s Bro chure.  
The study team  will probe, via discussion wit h the subject , for the occu rrence of AEs 
during each subject encounter and record the informat ion in the site’s source documents.  
Adverse events will be recorde d in the patie nt case-repor t form.  Adverse  events will be 
described by duration (start and sto p dates and t imes), severit y, outcome, treatment,  and 
relation to study drug, or i f unrelated, the cause.  
AE Severity  
The National Canc er Institute’s Common Term inology Criteria for Adverse E vents 
(CTCAE)  Version 4.0 should be used to assess and grade AE se verity, inclu ding laboratory  
abnormalities  judged to be  clinic ally significant. Only for the specific Adverse Event of 
change in l iver enzymes will The National  Canc er Institute ’s Common Termin ology 
Criteria for Adverse E vents (CTCAE) Version 5.0 be used.  If the experience is not covered 
in the mo dified cr iteria, the  guidelines shown i n Table 2 below should be used to grade 
severity.  It should be pointed out tha t the term “sever e” is a measure of intensi ty and that a 
severe  AE is not necessarily serious.  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 21 of 30 
 Table 2.  AE Severity Grad ing 
Severity (Tox icity Grade)  Descrip tion 
Mild (1)  Tran sient or mild discomfort; no limitation in activity; no medical 
intervention or  therapy required . The subj ect ma y be aware  of the sign 
or symp tom but tolerates it reasonably w ell. 
Moderate (2)  Mild t o moderate limita tion in activ ity, no  or minimal medical  
interven tion/therapy required.  
Severe (3)  Marked limitation in activity, medi cal inter vention/ therapy re quired , 
hospital ization s possible.  
Life-threaten ing (4)  The subject is at risk of death due t o the adverse exp erience as it  
occurr ed. This does not r efer to a n experience that hypothetically 
might have caused death if it were mo re severe . 
 
AE R elationshi p to S tudy Drug  
The relationship of an AE to the study drug should be  assessed using the follo wing the 
guidelin es in Table 3. In delineating AE relationship, research team will consider a dverse 
events tem porally or other wise clear ly related to administration of the drug in relation to 
noted deviation from natural history of  SARS -CoV -2 infectio n. 
Table 3.  AE Rel ationship to Study Drug  
Relationship  
to Drug Comment  
Definitely  Previously kno wn toxicity of ag ent; or an ev ent that foll ows a reasonable temporal 
sequence from admin istratio n of the drug; that fo llows a  known or exp ected response 
patte rn to the suspected  drug; that i s confirmed by stopping or reduci ng the dosage of 
the drug; and th at is not ex plain ed by any oth er reasonable  hypothesis.  
Probably  An event that follows a reason able temporal sequence  from a dministration  of the 
drug; that f ollows a k nown or e xpected respo nse pattern to the suspected drug ; that is 
confirme d by stopping o r reducing t he do sage of the d rug; and that  is unlikely to be 
explained by the known cha racteris tics of the subject’s clinica l state or by  other 
interventions . 
Possibl y An even t that follow s a reasonable temporal sequence from administratio n of the 
drug; that follows  a known or expect ed response p attern to that suspected drug; but 
that could  readily  have been produced by  a numb er of other f actors.  
Unrelated  An event th at can be  determined w ith certainty to have no relation ship to the study 
drug.  
11.2 Serious Adverse Expe rienc es (SAE)  
An S AE is defined  as any AE occurring at any dose that results  in any of the following 
outco mes:  
• death 
• a life -threatening adverse ex perience  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 22 of 30 
 • inpatient hospitalizati on or prolongation of existing ho spitalization  
• a persistent or sig nificant dis ability/incapacity  
Other import ant medical events may also be considered an SAE when , based on 
appropriate  medica l judgment, t hey jeopardize the s ubject or require i ntervention  to prevent 
one of  the outcomes listed.  
 
11.2.1  Serious Adverse Experience  Reporting  
Study sites w ill do cument all SA Es that occur (whether or not related to stud y drug) per 
Lifespan IRB guide lines . The collectio n period for all SAE s will beg in after informed 
consent is obtained and 28-days after last administration of Maraviroc .  
In accor dance with the  Pfizer con tractua l terms,  standard operating procedures and policies 
of the Lifespan  Institutional Rev iew Bo ard (IRB)  the Investigato r or one of the st udy 
members will report SAEs to the IRB . SAE and AE documentation  will occur in  REDC ap. 
11.3 Medical  Moni toring  
Dr. Timo thy Fla nigan  shou ld be contacted directly at these numbers to  report medical 
concerns or questions regarding safety.  
Phone : (401) 639-2433  
Pager : (401) 350-5056 
   
12 DISCONTINUATION AND REPLACEMENT OF SUBJECTS  
12.1 Early D iscont inua tion of Study Drug  
A subject may be  discontinu ed from study treatment at any time if the s ubject  or the 
investigator  feels that it is not in the s ubject ’s best  interest to contin ue.  The following is a 
list of possible reasons for study treatment disconti nuatio n:  
• Subject withdrawal of c onsent (or assent)  
• Subject is not compliant with stu dy procedures  
• Adve rse eve nt that in the opinion of the investi gator would b e in the best inter est of the 
subject to discontinue study treatment , includin g sto ppage criteri a for orthostatic 
hypotension  
• Protocol violation requiring discontinuation of  study t reatment  
• Drug supplier  (Pfizer) request for early termination of study , after which study drug 
cannot be reasonably pro vided to subjects at no cost to them  
• Positive pregna ncy test ( females)  
• Pursuit of comfort measures only, i npatient hospice referral  or tra nsfer to inpatient 
hospice f acility   
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 23 of 30 
 If a subje ct is withdrawn from treatm ent due to an adv erse eve nt, the subject will be 
followed and treated by the study tea m until th e abnormal parameter  or symptom has 
resolved or stabilized.   
Subjects who are discharged from the hospital will not cont inue taking Maraviroc  outside 
the hospi tal. Early completion  prior to seven days of therapy will not be considered  early 
withdrawal  from the study. All subjects who disconti nue st udy treatment will undergo  an 
early discontinuation visit as soon as poss ible and will be encouraged to complete al l 
remaining scheduled  research  labwork  (excep t in the inst ance of comfort mea sures a nd 
hospice) . Subjects are free to withdraw from participation at any time, for any reason, 
specified or unspecified, and without p rejudice. 
Reasona ble attempts will be made by the investigator to provide a re ason for subject 
withdrawals.  The reason  for th e subject’s w ithdrawal from the study will be sp ecified in 
the subject’s source documents . 
12.3 Withdrawal of Subjects from the Study  
A subject may  be w ithdrawn  from the study at  any time if the subject  or the inves tigator  
feel that it is  not in the subject’s best  interest to continue.    
All subjects are free t o withdraw from participation at any time, for any reason, specifi ed or  
unsp ecified, and without prejudice.  
Reasonable att empts will be made b y the investigator to provide a reason fo r subje ct 
withdrawals.   The reason for the subjec t’s w ithdrawal from the study will be specified in 
the subject’s source documents.   As not ed ab ove, subjects who discontinue study treatment 
early  should have an earl y discontinuation visit. Refer to Section  10 for  early termination  
procedure s.   
12.4 Replacement of Subjects  
Subjects who withdraw from the study treatment will  not be replaced . Subjects who are  
discharged from the hospital due to clinical impro vement prior to co mpleting the 7 -day 
course will not be replace d. Subjects may be added to the study to replace subjects with 
incomplete data  (said subjects will continue to receive Maraviroc) stemming from research 
bloodwork processing errors due to mishandling o f shipments  resulting in  compromised 
fidelity  of samples. 
13 PROTOCOL VIOL ATIONS  
A protocol violation occu rs when the  subje ct or investigator  fails to adhere to significant 
protocol requir ements affect ing the inclusion, exclusion, subj ect safet y, and primary 
endpoint criteria.  Protocol violations for this study include, but are  not limite d to, the 
following:  
• Failure to meet in clusion/exclu sion crit eria 
• Use of a prohibited concomitant medica tion 
• Non-comp liance with study drug regimen, in cludi ng dose-reduction protocol  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 24 of 30 
 • Failure to comply with Good Clinica l Practice (GCP) guidelines  will also result in a 
protocol vi olatio n. The Investigator  will det ermine if  a protocol violation will result 
in withdr awal of a s ubject. 
When a protocol violation oc curs, it will b e discus sed with the Investigator and a Protocol 
Violation Form detailing the violati on will be genera ted. This f orm wi ll be signed by the 
Investigator  and forwarded to the IRB .  Document ation of Protocol Violations  will be 
stored on IRB.net.  
14 DATA SA FETY MONITORING   
Despite Maraviroc being well -tolerated without significant  side effects in previous trial s 
and its current use i n patients with HIV, vigilance  and at minimum  daily a udits of subj ects’ 
objective and subjective respon se to treatment  is required given  the aggressiveness of 
SARS -CoV -2. The trial team will be responsi ble for eliciting adverse events and reviewi ng 
inpatie nt documentation daily. The trial  team has  specifically pre -define d possible  adverse 
events. Howe ver, gi ven the multitude of possible  adve rse events, the study prot ocol is not 
able to d efine all of them  in advance as many may not  lend themselves t o satisfa ctory 
definition during trial design.  Adverse events will be monit ored by the Investigators and  
Medic al Monito r during the study.  
14.1 POSTURAL DIZZINESS AND ORTHOSTATIC HYPO TENSION  
In healthy volunteers, orthostatic hypotension  four ho urs a fter adm inistration of Mara viroc  
was observe d in subjects rece iving  high doses (600mg or more)  of Marav iroc versu s 
placeb o. Per package labeling, i t is recommended that users who also take an anti -
hyper tensive medication b e asked about symptoms o f orthosta tic hypo tension. Of note, in 
two Phase 3 tri als, 8% of patient s in active  (exposure ad justed rate of 14.1 per 100  pt-yrs) 
and placebo drug groups described postural dizziness, but the rate of discontinu ation due to 
syncope  or orthostatic hypoten sion betwee n the M araviroc grou p and t he placebo were 
reported at 0.5% .  Of the 840 subjects who received one dose  of Maravi roc, 2 d iscontinued 
therapy (1 due to syncope, 1 due to orthostatic hypotens ion, with an exposure adjusted ra te 
of .07 per 100 p t-yrs). 18  It is possible that the  rate o f dizziness is re lated to the length of 
therapy. In a pilot  study of investi gating two months of M araviroc (300 mg BID) in 11 
colorectal cancer patients with meta stasis to the  liver, Grade 1 dizz iness was observed in 1 
patient . No patient had dizzin ess Gra de 2 or higher (e xposure adjusted rate of 5.1 per 100 
pt-yrs).13    
 
Based on  exper ience with t he Phase 3 trial, in which both the M araviroc group and Placebo 
had exposure adju sted rates of 14.1 v ersus 17 .1, respectively, 6 to 8  patie nts are expecte d 
to experienc e postural dizziness in a cohort o f 40 patients who complete 7 days  of therapy.  
Based o n a similar calculation for o rthostatic hypotension, we woul d expect to see less than 
one patient exp erience orthostatic hypotension requiring discontinua tion of therapy . We 
recognize that patients with SARS -CoV -2 may be pre-dispo sed to postural dizziness and 
orthostatic hypotension  because of  their illness and poo r oral  intake , and therefore ; 
 
13 Halama N, Zoernig I, Bertel A, et a. T humoral im mune cell exploitation in colorectal cancer metastases can 
be targeted ef fectively by anti -CCR5 therapy in cancer patients. Cancer Cell. 2016;29(4):587 -601 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 25 of 30 
 observed orthostasis  is unlikely to be from Maraviroc given the low a forementione d 
incidence in  Phas e 3 trials.   Furthermore, a stu dy of ort hostatic vital signs check ed three 
times  in one day in  elderly  patients admitted to t he hospital (most comm only for stroke, 
infectious diseases,  or other reasons) revealed that 2/3  of patients had one set of abnormal 
orthostatic vitals14. Therefore , we outl ine below dose -reduction a nd stop criteria per pa tient 
to address the  risk for orthost asis.  
 
Rates, severi ty, and relationship  of postural dizziness, as well as exposure adjusted rates for 
orthost atic hypotension resulting in discontinuation, wil l be calc ulated at the point in whi ch 
10 patients have received more than four d oses of treatme nt. The Medical Monit or may 
request trial  stoppage in the instance that an unacceptable rate o f discontinuation  due to 
orthostatic hypotension reasonably attribu table to Maraviroc is observed.  
  
14.1.1 Dose reducti on pr otocol:   
All dose-reductions will be recorded in each subj ects CFR.  
 
Patient s will be initiated on Maraviroc 300 mg twice daily. Or thostatic vitals will be 
obtained four hours after the first dose  unless otherwise contra -indicated . If sympto matic  
and orthostatic,  the next dose of Maraviroc can be held  and inpatient team will be advi sed 
to review anti-hypertensive strategy, diuretic use  and consider  supplemental intravenous 
fluid if patient is anorexi c and dehydrated . Subjects  will be  re-trialed on 300 mg o f 
Maraviroc the next day. If still orthostatic, the patie nt will be re-trialed at 150 mg of 
Maraviroc the next day . Persistent orthos tasis probably or definitely at tributable  
(ortho stasis tha t develo ps aft er starting Maravi roc that was no t present at  baseline)  may 
prompt disc ontinuation of trial medicine with consideratio n of severit y of orthostasis and 
after discussion with subject and  inpatient  care team.  Withdrawing subject s will be asked t o 
participate in a  withdrawal visit as outlined  above in se ction 10.14 . Orthostatic v itals will 
be repeated during course of treatme nt at the di scretion of inpatient care team.    
 
The aforemen tione d dose reduct ion protocol will apply to subjects on a moder ate or s trong 
CY3PA4  inhibitor, who will be ini tiated on Ma raviroc 150 mg twice daily , with  the 
distinction that dose reduction would occur to  Maravir oc 150 mg once  daily. For subjects  
on a moderate  or strong CY3PA4 inducer, the subject  will be initiated a t Maravi roc 600 mg 
twice daily. If orthostatic  as described  above , dose -reduction to Marav iroc 300 mg  twice 
daily, followed by Maraviroc 1 50 mg twice daily will be pu rsued. Lastly, g iven the  clinica l 
context,  intubated and sedated subjects  in an intensive  care uni t will be con tinued on 
Maraviroc 300 mg  twice witho ut monitori ng for postural  dizziness of orthosta sis. 
Alternati ve causes for hypotensi on in this population should be explore d prior to dose 
reducing  Maraviroc.  
 
14 Weiss A., Grossman E., Beloosesky Y., et al.(2002) Orthostatic hypotension in acute geriatric ward : is it a 
consistent fi nding? Arch Intern Med 162:2369 –2374.  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 26 of 30 
 14.2 CARDIAC EVENTS  
In a safety analysis of two P hase 3 trials  of Maraviroc involving 84 0 HIV -infect ed subj ects 
who received a t least one dose of Maraviroc  over 34 weeks , including 426 who rece ived 
twice dai ly dosing, 1.3% o f subjects had cardiov ascula r event s. More subjects  in the 
Maraviroc grou p experi enced cardiov ascular events  than in the  placebo gro up, but th e link 
to the drug was unclear and symptoms occurred only in th ose with kno wn cardiac disease.20 
Given that our population may higher baselin e risk of cardiac events , subjects with Acut e 
Coronary  Syndrome  (ACS) within 6 months of enrollment  will be excluded. In addition,  
participants will be mo nitor ed for sympt oms of cardiac isch emia, heart failure o r arrythmia  
with further investig ation driven  inpat ient care tea m. The study team does not  plan to 
routinely ch eck cardiac biomarkers in a symptomatic  patients. The safety m onitor may 
request  trial stoppage if a grade 3 or 4 adverse  cardiac e vent occurs in any trial partici pant 
reasonably attributable  to Maraviroc.  
Maraviroc  does not affect  the QT inter val. 
14.3 HEPATOT OXICITY  
NIH LiverTox Databa se gives a likelihood  score D, ind icating that Maraviroc is a possible 
rare cause of clinically a pparent liver injury.  The Maraviroc la bel include s a w arning about  
hepatotoxicity , based on observed  systemic a llergic r eaction prio r to development of 
hepatot oxicity  report ed in  two subjects enr olled in pre -licensure clinical trials. Both 
patients were w omen, ages 24 and 27,  who developed fe ver, fatigue, and rash prior  to liver 
test abnorma lities within 1 to 3 we eks of st arting Marav iroc.  In bot h instances, other 
potent ial causes were present,  but no other diagnosis was confirmed. For these reasons, 
hepa titis and hepatic fai lure are listed a s adverse  events  in the prod uct label which include s 
a boxed warning abou t hepatot oxicity. In post-marketin g surveillanc e, one case of life -
threatening hepato toxicity, which eventually led to liver transplantation, aft er 4 doses of 
Maravir oc has been descr ibed in a  patien t who also r eceived isoniazid and trimethoprim -
sulfametho xazole. In two Phase 3 trials  of HIV patients o n Maraviroc  for an average of 34 
weeks , no overall increase in  ACTG -defined  Grade  3 of 4  (>5 x ULN ) liver function test  
abnormalities we re observ ed in a  clinical tr ial of M araviroc in treatment -experienced 
subjects wit h HIV. 15  
Short-term use of Maraviroc may be gener ally well -tolerated. Short -term use of Maraviroc 
was not associated with hepatic intol erance in a study of 63 HIV -1 positive  individu als 
receiving 10 -day Maravir oc monotherapy. 16 
At baseline, clinic al trials enr olling y ounger S ARS -CoV-2 patients  have demons trated 
hepatocellular tran saminitis (AST and ALT >2 x ULN) in 20 -40% of patients at t ime of 
enrollment 13 d ays (median) from  symptom onset.   In clinical  practice , hepatocellular 
transaminitis as hi gh as 4 x ULN  is freq uently e ncoun tered in hosp italized pat ients. 4 
 
15 Selzentry (Maraviroc) [package insert] N ew York, NY : Pfizer  Inc; 2007  
16 Fatkenheuer  G, Pozniak  AL, Johnson  MA, et al. Efficac y of short -term monotherapy with maraviroc, a new 
CCR5 antagonist, i n patients infected with HIV -1, Nat Med , 2005 , vol. 11  (pg. 1170 -2) 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 27 of 30 
 Given the high in cidence of hepatitis at baseline in SARS -CoV -2 patients, we  expect to 
observe hig h incidence of  low-grade l iver f unction test abnorma lities  during lab 
monitoring. Therefor e, we el ect to implem ent Comm on Te rminology Cri teria for Ad verse 
Events (CTCAE) v5.0,  which incorporates change in liver function testing from b aseline to 
characteriz e AE grade. The r ecommenda tion f rom the FDA l abeling  is to obtain liver 
function tests pri or to starting the dr ug and a gain should sympto ms such as r ash occur. We 
will obtain both baseline and repeat liver function test should allergi c symptoms such as  
rash occ ur. Liver function  testing obtained per routine care will be collected daily.  
Exposure adjus ted rat es of Grade 3 or 4 changes in liv er function testin g result ing in 
discontinuation wil l be calcula ted at the point in which eight  patients have received more 
than four doses  of treatmen t. The Medical Monitor may request trial  stoppage  in the 
instance that an u nacceptable rate of Grade 3 or  4 chang es in liver f unction testing resulting 
in discontinuatio n reasonably attributable to Mara viroc is observed.   
14.4 OTHER  ADVERSE EVENTS  
Additional ad verse events commonly reported include f ever, cou gh, rash, abdomin al pain, 
and increased  risk of infectio ns inclu ding upper re spirator y tract infections.  Trial  data was  
obtained from patients  with H IV infection at greater r isk for infection, Immune 
Recons titution Syndrome (IRIS), and malignancy  which ma y have been secon dary reasons 
for fever . Acknowledging  the anticipated frequency of fever  and cough in SARS -CoV -2 
patients, t he study team will monitor f or evidence of seconda ry infect ion. 
14.5 UNANTICIPATED ADVE RSE EVE NTS  
As the above anticipated adver se events wer e noted in a population which vari es from o ur 
study  population hospitalized a dults with  SARS -CoV-2 infection, it is also important to 
monitor for un expected adverse event s. Serious, un -anticipated a dverse ev ents including 
sepsis, shock, respi ratory failure, or death will be closely monitored for an d report ed. As 
this is a population with a hig h risk of adverse outcome related to SARS -CoV -2 itself, 
course of infection  in pa rticipan ts will be monitored  for any deviation from the natural 
histor y of SAR S-CoV -2 infection, based on available clinical tr ial data  and clinical 
experience.  The monitor ma y request trial stoppage if any unexpected grade 4 event oc curs 
in unacc eptable rate d ue to Maraviroc . They may  also req uest stoppage if there is  noted to 
be a serious adver se eve nt temporally  or other wise clearly  related to administration of the 
drug in a ny participant , and/or if there is noted to be a pattern of  deviation from natural 
history of SARS -CoV -2 infect ion towards worsening symptomatolo gy and /or incre ased 
incidenc e of adverse events. The monitor may request trial stoppage if any unexpected 
grade  4 event probably or definitely attributable to Maraviroc o ccurs at an unacceptable  
rate. 
15 STATISTICAL METHODS AND  CONSID ERATIONS  
Prior to the analysis of the f inal study data, a d etailed Statist ical Analysis Plan (SAP)  will 
be written de scribing all analys es tha t will be performed.  The SAP will contain a ny 
modification s to the analysis plan described below.   
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 28 of 30 
 15.1 Data S ets Ana lyzed  
All eligible  subjects who  receive  at least one dose o f the study dru g, or who have had more 
than one set of serum samples availabl e for bioma rker testing  will be included in the 
analysis.  
15.2 Demogra phic and Baseline Charact eristics  
The following demographic variables  at screening w ill be summarized : race, gende r, age, 
height and weight , BMI, hemodia lysis, cardiovascular dis eases (hypert ension, known 
valvular disease,  cardiomyopathi es and/or LV systolic  or diastolic dysfunction), and 
pulmon ary disease (including OSA, COPD, asthma , interstitial lung disease, cysti c fibrosis, 
bronchiectasis, lung transp lant, lung cancer, pulmon ary hypertens ion), oxygen device and 
requirement at time of enrollmen t, oxygen s aturation on ambient air at time of enrollment , 
and time from onset of sympto ms to  presentation to enrollment . 
15.3 Analysis of Endpoints  
Contin uous data  obtaine d wil l be expresse d by mean ± sta ndard deviation (SD) or 
interquartile  range, as applicable.   Categor ical variables wil l be reported as frequency and 
percentages. ICU L OS (and mechanical ventilation LOS, r especti vely) will be regressed on 
available  laborat ory a nd biomarker data using mult ivariable linear regression.  All ana lysis 
will be conducte d in a professional statist ical program . Mortality and  percent of study 
population reaching clinical improvement at Day 7 will be compared to published results  
from Remdesivir for 5 or 10 Days in P atients with Severe C OVID -19, and other available 
clinical trials including The Randomized  Evaluation of COVID -19 therapy ( RECOVERY) 
Trial.  
15.4 Interim Analysi s 
Refer to Section 14 regarding interim adverse event  analysis.   
16 DATA COLLECTION, RETENTION AND MONIT ORING  
16.1 Data Co llection Inst ruments  
The Investigator will pre pare and maintain a dequate and accurate source documen ts 
designe d to record all observations  and other pertinent data fo r each subject treated w ith the 
study d rug. Data will be stored in REDCap, a HIPAA  comp liant data capture tool Study 
personnel  will enter da ta from source document s corresponding to a subject ’s visi t into th e 
protocol -specific  electro nic Case Report Form (eCRF) when the information c orresponding 
to that visit is availabl e. Clinical data will be recorded using a modified  WHO –
Internati onal Severe Acute  Respiratory and Emerging Infections Consort ium ( ISARIC ) 
Rapid Version C ase Record Form. Daily d iary cards recording data on a seven-category 
ordinal scale will be capture d in R EDCap.  Subjects will not b e identified by name 
inREDCap, but will be i dentified by a subject number and initials.  
 If a corre ction is required for  an eCRF, the tim e-and-date stamps trac k the person  entering 
or updating eCRF data and creat es an  electron ic audit tr ail.  
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 29 of 30 
 The Invest igator is responsible for  all information colle cted on subjects enrolled in this 
study.  All  data coll ected during the cour se of this study must be r eviewed and v erified for 
completeness and accuracy b y the Investig ator.    
16.2 Subje ct Confide ntiality  
In or der to maintain subject con fidentiality, only a subject number a nd subject initials will 
identify all study subjects  on CRFs and other  documentation  in REDCap.  Only specimen 
ID will be provided to InCell Dx , the Elias Lab  and the Prlic Lab  during sample analysis. 
When s ubmitting data to a peer -review jour nal, only age, gender, race and pr e-existing 
medical conditions will be disclosed for each subject.  
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIO NS 
The study will be conducted ac cording t o the Declaration of Hel sinki, Protection  of Human 
Volunteers ( 21 CFR 50), Institutional  Review Boa rds (21 CFR 56), and Obligation s of 
Clinical Investigators  (21 CFR 312).  
To maintai n confide ntiality, all laborator y specimens, evalu ation forms, re ports and  other 
records wil l be i dentified by a co ded number and initial s only. The Investigator must also 
compl y with all  applicable privac y regulations (e.g., Health Insurance Portability and 
Accountability Act o f 1996 , EU Data Protect ion Directive 95/46 /EC). 
17.1 Protocol Amendments  
Any amendment to the protocol will be writte n by the Investigator .  Pro tocol  amend ments 
cannot  be imp lemen ted without prior written IRB  approval except as necessary to elimin ate 
immediate safety hazards to p atien ts.  A protocol am endm ent intended to eliminate an 
apparent immediate hazar d to patients may be implemented immedia tely, p rovided the 
IRBs ar e notifie d within five working days.  Protocol amendments will be tracked on 
IRB.net.   
17.2 Institutional Revie w Boards  
The protoco l and  consent form will be review ed and approved by the Lifespan IRB prior to 
study initiation.  Serious adverse ex perienc es regardless of causality will be reporte d to the 
IRB in accordance with  the standard operati ng procedures and  policies of th e IRB , and  the 
Investigator will keep the IRB  inform ed as to the p rogress of the study.    
Any docu ments tha t the IRB  may need to fulfi ll its responsibi lities (such as protoc ol, 
protocol amendments, I nvestigator’s Brochure, con sent forms, in formation conce rning 
patient recruitment, pay ment or  compensation procedures, or other  pertinent informat ion) 
will be submi tted t o the IRB .  The I RB written u nconditional approval of the study protocol 
and the infor med consent form w ill be in the possession of the Invest igator bef ore the stu dy 
is initiated.  The IRB  unconditional approval s tatement will be tr ansmitted  by the 
Investigator to Pfizer prior to initiation of t he study .  This approva l must refer t o the study 
by exact protoc ol title and numbe r and s hould identif y the documents reviewed and the 
date of review.  
Protocol and/o r informed consent mod ifications or cha nges m ay not be initia ted without 
prior written IRB  approval e xcept whe n necessary to  eliminate immediate hazard s to the 
Protocol : Open -Label Study  of Maraviroc in Hospitalized  Individual s Diagnosed  with S ARS -CoV -2   
 
Version #:  2.8 Version Date: 11/6/2020  Page 30 of 30 
 patients or when  the change(s) in volves only logistical or administr ative aspects of the 
study.  Such modification s will be  submitt ed to the IRB and written verification that the 
modification was s ubmit ted and subseq uently approved should be o btained.   
The IRB must be inform ed of revisio ns to other documents originally su bmitted for revie w; 
serious and/or une xpected adverse e xperiences occurri ng during the study in accordance 
with the standard oper ating procedure s and policies of the IRB; new information  that may 
affect adver sely the safe ty of the patients of the conduct o f the study; an a nnual updat e 
and/or r equest for re -approval; and when th e study has been completed.  Updated 
documents will be stored on IRB.net.  
17.3 Informed Consent Form  
Infor med consent wil l be obtained in accordance  with the Declaration of Helsinki, ICH 
GCP, US Code of Fe deral Regulations for Protec tion of Hu man Subjects ( 21 C FR 
50.25[a ,b], CFR 50.27, a nd CFR Part 56, Subpar t A), the Health Insurance Portability and 
Accountab ility Act (HIPA A, if applicable) , and loca l regulations.  
The conse nt form genera ted by the Investigator mus t be approved by the IRB .  The  written 
conse nt document will e mbody the elements  of informed consent as  described in the 
International Conference on Harmonisation and w ill also c omply with loc al regulations.  
A properly  executed, written, informed  consent will be obtained from each subj ect prior to 
entering the subjec t into the trial.  Informat ion should be g iven in bo th oral and written 
form and subjects must  be given am ple opportuni ty to inqu ire about details of the st udy.  A 
copy of the signed  consent form will be scanned into Epic an d the original  will be given to 
the subject . 
17.4 Publications  
The publicatio n or presentation  of any study results shall comply with all appl icable 
privacy laws, including, but n ot limited to, t he He alth Insurance Po rtability and 
Accounta bility Act of 1996.   
 